Chiome Bioscience Inc. [4583.T]
TOKYO, Apr 14 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) announced today that its board of directors approved the issuance of restricted shares as part of a compensation program for executives.
The new share issuance, scheduled for May 11, 2026, involves issuing ordinary shares worth a total of ¥20.4 million. The shares will be allocated to three executive officers based on their contributions to the company. Each officer will receive shares valued at ¥102 per share, totaling 199,900 ordinary shares. The purpose of this issuance is to align the interests of executives with those of shareholders by tying compensation to stock performance. This initiative was initially approved during the company's 18th Ordinary General Meeting held on March 25, 2022, and further detailed in subsequent meetings.
The restricted period for these shares runs from May 11, 2026, until the executives' departure from their positions, with certain conditions allowing for early release of restrictions. Under the agreement, the shares cannot be transferred, pledged, or otherwise disposed of during the restriction period. Should an executive resign or retire within the initial restricted period, the company reserves the right to reclaim the shares without compensation, except under special circumstances recognized by the board. Upon completion of the restriction period, the shares will be freely tradable subject to meeting continued service requirements. This move underscores Chiome Bioscience’s commitment to incentivizing long-term growth and aligning management goals with shareholder value.
🟡 Confidence: Standard AI-translated content.